Introduction: Angiotensin-converting enzyme inhibitors (ACEIs) have shown promising results in decreasing the incidence and the severity of ischemic stroke in populations at risk and in improving ischemic stroke outcomes. Objectives: The objectives of this study were to investigate the impact of ACEI use before ischemic stroke onset on in-hospital mortality and to identify the independent predictors of in-hospital mortality among patients with ischemic stroke. Methods and Materials: A retrospective cohort study of all patients with acute ischemic stroke attending the hospital from June 1, 2008 to November 30, 2008 was performed. Data were collected from medical records and included demographic information, diagnostic information, risk factors, previous ACEI use, and vital discharge status. Statistical Package for Social Sciences (SPSS) version 15 was used for data analysis. Results: A total of 327 patients with acute ischemic stroke were studied, of which 119 (36.4%) had documented previous ACEI use. During the study period, 52 (15.9%) of the patients with acute ischemic stroke died in hospital. In-hospital mortality was significantly lower among patients who were on ACEI before the attack (P = 0.002). The independent predictors for in-hospital mortality among patients with ischemic stroke were age ≥65 years (P < .001), the presence of diabetes mellitus (P = .012), renal impairment (P = .002), and heart failure (P = .001). Moreover, prior use of ACEI was an independent predictor for survival after ischemic stroke attack (P < .001). Conclusion: This study provides evidence that the prophylactic administration of ACEI before ischemic stroke may be a potential life-saving strategy. Furthermore, knowledge of in-hospital mortality predictors is necessary to improve survival rate after acute stroke.
American Heart Association.Heart Disease and Stroke Statistics-2006 Update. Dallas, TX: American Heart Association; 2006.
2.
World Health Organization.Cardiovascular diseases. www.who.int/mediacentre/factsheets/fs317/en/print.html . Accessed March 6, 2010.
3.
Numminen H., Kaste M., Aho K., Waltimo O., Kotila M.Decreased severity of brain infarct can in part explain the decreasing case fatality rate of stroke. Stroke. 2000;31(3):651-655.
4.
Centers for Disease Control and Prevention.Decline in deaths from heart disease and stroke-United States, 1900-1999. MMWR Morb Mortal Wkly Rep. 1999;48(30):649-656.
5.
Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-153.
6.
Selim M., Savitz S., Linfante I., Caplan L., Schlaug G.Effect of pre-stroke use of ACE inhibitors on ischemic stroke severity. BMC Neurol. 2004;5(1):10-14.
7.
Fuentes B., Fernández-Domínguez J., Ortega-Casarrubios MA, SanJosé B., Martínez Sánchez P., Díez-Tejedor E.Treatment with angiotensin receptor blockers before stroke could exert a favourable effect in acute cerebral infarction. J Hypertens. 2010;28(3): 575-581.
8.
Francis GSACE inhibition in cardiovascular disease. N Engl J Med. 2001;342(3):201-202.
9.
Basri H., Azman Ali R.Predictors of in-hospital mortality after an acute ischaemic stroke. Neurol J Southeast Asia. 2003;8(1):5-8.
10.
Lisabeth LD , Diez Roux AV, Escobar JD, Smith MA, Morgenstern LBNeighborhood environment and risk of ischemic stroke: the brain attack surveillance in Corpus Christi (BASIC) Project. Am J Epidemiol. 2007;165(3):279-287.
11.
Al-Wabil A. , Smith MA, Moye LA, Burgin WS, Morgenstern LBImproving efficiency of stroke research: the Brain Attack Surveillance in Corpus Christi Study. J Clin Epidemiol. 2003; 56(4):351-357.
12.
Morgenstern LB , Smith MA, Lisabeth LD, et al. Excess stroke in Mexican Americans compared with non-Hispanic whites: the Brain Attack Surveillance in Corpus Christi Project. Am J Epidemiol. 2004;160(4):376-383.
13.
Warlow C., Sudlow C., Dennis M., Wardlaw J., Sandercock P.Stroke. Lancet. 2003;362(9391):2121-2124.
14.
Bamford J., Sandercock P., Dennis M., Burn J., Warlow C.Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337(8756):1521-1526.
15.
Hacke W., Kaste M., Fieschi C., et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). . JAMA. 1995;274(13):1017-1025.
16.
Hajat C., Dundas R., Stewart JA, et al. Cerebrovascular risk factors and stroke subtypes: differences between ethnic groups. Stroke. 2001;32(1):37-42.
17.
Pinto A., Tuttolomondo A., Di Raimondo D., Fernandez P., Licata G.Cerebrovascular risk factors and clinical classification of strokes. Semin Vasc Med. 2004;4(3):287-303.
18.
Waring WS, Jamie H., Leggett GEDelayed onset of acute renal failure after significant paracetamol overdose: a case series. Hum Exp Toxicol. 2010;29(1):63-68.
19.
Kernan WN, Viscoli CM, Brass LM, et al. The stroke prognosis instrument II (SPI-II): a clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke. Stroke. 2000;31(2):456-462.
20.
Asawavichienjinda T., Boongird P.Cerebrovascular disease in North East Thailand . Neurol J Southeast Asia. 1998;3(1):27-33.
21.
Di Sciacca R., Tuttolomondo A., Di Raimondo D., La Placa S., Pinto A., Licata G.Cardiovascular drugs pre-treatment related prognosis in patients with acute ischemic stroke. Nutr Metab Cardiovasc Dis. 2008;18(suppl 1):S45.
22.
Chitravas N. , Dewey HM, Nicol MB, Harding DL, Pearce DC, Thrift AGIs restrike use of angiotensin-converting enzyme inhibitors associated with better outcome? Neurology . 2007;68(20): 1687-1693.
23.
Frankel MR, Morgenstern LB, Kwiatkowski T., et al. Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. Neurology. 2000;55(7):952-959.
24.
Lewington S. , Clarke R., Qizilbash N., Peto R., Collins R.;. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360(9349):1903-1913.
25.
Kranzhofer R., Schmidt J., Pfeiffer CA, Hagl S., Libby P., Kubler W.Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19(7):1623-1629.
26.
Daugherty A. , Manning WM, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105(11): 1605-1612.
27.
Yoshimoto T. , Fukai N., Sato R., et al. Antioxidant effect of adrenomedullin on angiotensin II-induced reactive oxygen species generation in vascular smooth muscle cells. Endocrinology. 2004;145(7):3331-3337.
28.
Jamrozik K. , Broadhurst RJ, Forbes S., Hankey GJ, Anderson CSPredictors of death and vascular events in the elderly: the Perth Community Stroke Study. Stroke. 2000; 31(4):863-868.
29.
Szczepańska-Szerej A., Wojczal J., Belniak E., Krasińska-Czerlunczakiewicz H., Stelmasiak Z.Does diabetes mellitus affect the course and prognosis of ischemic stroke?Neurol Neurochir Pol. 2003;37(2):327-337.
30.
Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke-2002 update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases . American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002; 106(3):388-391.
31.
American Diabetes Association.ADA clinical practice recommendations. Diabetes Care. 2004;27(suppl 1):S1-S143.
32.
Koren-Morag N., Goldbourt U., Tanne D.Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology . 2006;67(2):224-228.
33.
Seliger SL, Gillen DL, Tirschwell D., Wasse H., Kestenbaum BR, Stehman-Breen CORisk factors for incident stroke among patients with end-stage renal disease . J Am Soc Nephrol. 2003; 14(10):2623-2631.
34.
Sweileh WMPredictors of in-hospital mortality after acute stroke: impact of renal dysfunction . Int J Clin Pharmacol Ther. 2008;46(12):637-643.
35.
Sweileh WM, Sawalha AF, Al-Aqad SM, Zyoud SH, Al-Jabi SWPredictors of in-hospital mortality after acute stroke: impact of gender. Int J Clin Exp Med. 2009;2(1):41-47.
36.
Wannamethee SG, Shaper AG, Perry IJSerum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke. 1997;28(3): 557-563.
37.
Appelros P. , Nydevik I., Sieger A., Terent A.Predictors of severe stroke: Influence of pre-existing dementia and cardiac disorders. Stroke. 2002;33(10):2357-2362.
38.
Zuliani G., Cherubini A., Ranzini M., Ruggiero C., Atti AR, Fellin R.Risk factors for short-term mortality in older subjects with acute ischemic stroke. Gerontology. 2006;52(4): 231-236.
